From the July 2019 issue of HealthCare Business News magazine
77063 - Screening digital breast tomosynthesis, bilateral (List separately in addition to code for primary procedure) — $25 (CMS average payment level, Technical Component)
Studies indicate that AI provides equivalent or better results than CAD for unaided interpretation by a radiologist while not adding to the reading time. This should help with the patient throughput, especially for busy imaging centers. One study reflected that sensitivity increased with AI from 83% to 86%, while specificity increased from 77% to 79%.
Ad Statistics
Times Displayed: 2839
Times Visited: 27 Fast-moving cardiac structures have a big impact on imaging. Fujifilm’s SCENARIA View premium performance CT brings solutions to address motion in Coronary CTA while delivering unique dose saving and workflow increasing benefits.
Another study compared AI with the performance of 101 radiologists. Using the Area Under the Curve (AUC) as a guide, the AI system had an AUC higher than 61.4% of the radiologists.
One primary goal of AI is to reduce false positive per image (FPPI). A study published in the Journal of Digital Imaging in April 2019 showed that using the AI-based CAD, as compared to CAD, resulted in a 69% decrease in FPPI. This should translate to significant savings to the healthcare industry.
The two prime directives of value-based healthcare are improving outcomes and controlling costs. The total cost for follow-up diagnostic mammogram studies ranges from $150 to $300 (global fees under Medicare payment rules). Ultrasound ranges from $120 to $150 (global fees under Medicare payment rules). These represent a $4 billion per year market.
When cancer is suspected, the only definitive way of ruling it out is by performing a biopsy and examining the tissue under a microscope. The cost of minimally-invasive breast biopsy ranges from $1,500 to $2,500. This translates to an estimated breast biopsy market of over $3 billion per year. Considering 30% of all biopsies turn out negative, even a 2%–3% improvement in ruling out false positives offers the promise of better outcomes and millions in cost avoidance. Overall, it’s a win/win for the patient and the payer. And AI is still learning.
About the author: James Laskaris is the senior clinical strategist at MD Buyline.Back to HCB News
